Pyrotinib

Generic Name
Pyrotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C32H31ClN6O3
CAS Number
1269662-73-8
Unique Ingredient Identifier
CJN36EQM0H
Background

Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

First Posted Date
2019-11-27
Last Posted Date
2019-11-27
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
100
Registration Number
NCT04179656
Locations
🇨🇳

Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

Phase 2
Not yet recruiting
Conditions
HER2-positive Breast Cancer
Interventions
Drug: Pyrotinib
Drug: Trastuzumab
First Posted Date
2019-11-12
Last Posted Date
2019-11-12
Lead Sponsor
xuexin he
Target Recruit Count
60
Registration Number
NCT04158856

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Female
Interventions
Drug: Pyrotinib
First Posted Date
2019-10-15
Last Posted Date
2023-11-21
Lead Sponsor
RenJi Hospital
Target Recruit Count
53
Registration Number
NCT04126525
Locations
🇨🇳

Renji Hospital, Shanghai, China

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

First Posted Date
2019-09-19
Last Posted Date
2019-09-19
Lead Sponsor
Jinming Yu
Target Recruit Count
60
Registration Number
NCT04095390
Locations
🇨🇳

Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

First Posted Date
2019-09-12
Last Posted Date
2019-09-12
Lead Sponsor
Fuzhou General Hospital
Target Recruit Count
77
Registration Number
NCT04088110
Locations
🇨🇳

Fuzhou general hospital, Fuzhou, Fujian, China

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

First Posted Date
2019-08-26
Last Posted Date
2020-05-19
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
12
Registration Number
NCT04066790
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Phase 2
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Pyrotinib
First Posted Date
2019-08-21
Last Posted Date
2019-08-21
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT04063462
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

First Posted Date
2019-06-25
Last Posted Date
2019-06-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
256
Registration Number
NCT03997539

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Phase 3
Conditions
Breast Cancer
Interventions
Drug: Placebo
Drug: Pyrotinib
First Posted Date
2019-06-10
Last Posted Date
2021-05-24
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
1192
Registration Number
NCT03980054
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, China

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

First Posted Date
2019-04-22
Last Posted Date
2019-04-22
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
35
Registration Number
NCT03923166
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy